NCT07337785 2026-01-22
CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
Tongji Hospital
Phase EARLY_PHASE1 Recruiting
Clinical Trials
12 trialsNCT07240974 2025-11-21
Safety and Efficacy of ZZSW-01 in Relapsed/Refractory B-cell Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase EARLY_PHASE1 Recruiting
NCT06972602 2025-05-15
High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed
Eye & ENT Hospital of Fudan University
Phase EARLY_PHASE1 Recruiting
NCT05432518 2025-04-25
Pilot Trial for Treatment of Recurrent Glioblastoma
AHS Cancer Control Alberta
Phase EARLY_PHASE1 Recruiting
NCT05651178 2025-01-07
Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients
Hrain Biotechnology Co., Ltd.
Phase EARLY_PHASE1 Recruiting
NCT06684639 2024-12-20
A Study on the Efficacy of GD2-CAR T Cells in the Treatment of Neuroblastoma
The General Hospital of Western Theater Command
Phase EARLY_PHASE1 Recruiting
NCT06732232 2024-12-13
A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
Shanghai Cell Therapy Group Co.,Ltd
Phase EARLY_PHASE1 Recruiting
NCT06718270 2024-12-12
a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia
Shanghai Changzheng Hospital
Phase EARLY_PHASE1 Recruiting
NCT06104215 2023-10-27
BGT007H Cells for the Treatment of Refractory Digestive System Tumors
The Affiliated Hospital of Xuzhou Medical University
Phase EARLY_PHASE1 Recruiting
NCT06104241 2023-10-27
BGT007 Cells for the Treatment of Refractory Digestive System Tumors
The Affiliated Hospital of Xuzhou Medical University
Phase EARLY_PHASE1 Recruiting
NCT04603872 2020-10-28
CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
Zhejiang University
Phase EARLY_PHASE1 Recruiting
NCT04283006 2020-08-21
A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies
Zhejiang University
Phase EARLY_PHASE1 Recruiting